Related Experiment Video
Updated: Jul 25, 2025

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness
Elena Oropeza1,2, Sinem Seker1,2, Sabrina Carrel1,2
1Aging and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Abstract:
Cell cycle dysregulation is prerequisite for cancer formation. However, it is unknown whether the mode of dysregulation affects disease characteristics. Here, we conduct comprehensive analyses of cell cycle checkpoint dysregulation using patient data and experimental investigations. We find that ATM mutation predisposes the diagnosis of primary estrogen receptor (ER)+/human epidermal growth factor (HER)2- cancer in older women. Conversely, CHK2 dysregulation induces formation of metastatic, premenopausal ER+/HER2- breast cancer (P = 0.001) that is treatment-resistant (HR = 6.15, P = 0.01). Lastly, while mutations in ATR alone are rare, ATR/TP53 co-mutation is 12-fold enriched over expected in ER+/HER2- disease (P = 0.002) and associates with metastatic progression (HR = 2.01, P = 0.006). Concordantly, ATR dysregulation induces metastatic phenotypes in TP53 mutant, not wild-type, cells. Overall, we identify mode of cell cycle dysregulation as a distinct event that determines subtype, metastatic potential, and treatment responsiveness, providing rationale for reconsidering diagnostic classification through the lens of the mode of cell cycle dysregulation..
Insights
The way cell cycle checkpoints are disrupted impacts breast cancer characteristics. Different disruptions influence cancer subtype, metastasis, and treatment response, suggesting new diagnostic approaches.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cell cycle dysregulation is fundamental to cancer development.
- The specific mechanisms of cell cycle dysregulation and their impact on cancer characteristics remain unclear.
Purpose of the Study:
- To investigate how different modes of cell cycle checkpoint dysregulation influence the characteristics of estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
- To determine if the mode of cell cycle dysregulation affects cancer subtype, metastatic potential, and treatment resistance.
Main Methods:
- Comprehensive analysis of patient data.
- Experimental investigations.
- Statistical analysis of mutation enrichment and survival data.
Main Results:
- ATM mutations are linked to primary ER+/HER2- cancer in older women.
- CHK2 dysregulation is associated with metastatic, treatment-resistant ER+/HER2- breast cancer in premenopausal women.
- ATR/TP53 co-mutation is enriched in ER+/HER2- disease and promotes metastatic progression, with ATR dysregulation inducing metastatic phenotypes in TP53 mutant cells.
Conclusions:
- The mode of cell cycle dysregulation is a critical determinant of breast cancer subtype, metastatic potential, and therapeutic responsiveness.
- Findings suggest reconsidering cancer diagnostics based on the specific mechanisms of cell cycle dysregulation.
More Related Videos
08:52Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization
Published on: August 16, 2015
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
Positive Regulator Molecules
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Inhibition of Cdk Activity
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...